Deep Genomics, a Toronto developer of treatments based on artificial intelligence, said today it has successfully used its own AI drug discovery platform to identify its first therapeutic candidate, a therapy for Wilson disease that the company plans to advance into clinical studies in 2021. DG12P1 is an oligonucleotide therapy designed to treat Wilson disease in patients who possess the exon skipping mechanism of Met645Arg . . .
